Large-scale testing (Phase 3)Study completedNCT01993212
What this trial is testing
A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%
Who this might be right for
Secondary Hypogonadism
Repros Therapeutics Inc. 120